Logo

Celltrion and Teva Report Results Updated Results of CT-P6 in P-III Study for Patients Receiving Neoadjuvant Treatment for HER2-Positive Early Breast Cancer

Share this

Celltrion and Teva Report Results Updated Results of CT-P6 in P-III Study for Patients Receiving Neoadjuvant Treatment for HER2-Positive Early Breast Cancer

Shots:

  • The study involves assessing of CT-P6 vs reference trastuzumab in 516 patients neoadjuvant period of the study entered the adjuvant treatment period
  • The study resulted in 9 patients (3.3%) in the biosimilar group and 6 patients (2.2%) in the reference group in the ITT population had recurrent or progressive disease @1 year. In adjuvant period relative dose intensity trastuzumab was 98.5% (2.97) and 98.8% (2.27) in the biosimilar and reference groups 
  • CT-P6 is a mAb targeted for a protein designed to recognize and bind to a specific structure or antigen in the body and is targeted to treat Neoadjuvant Treatment for HER2-Positive Early Breast Cancer

Click here to read full press release/ article | Ref: Center For Biosimilars| Image: Celltrion


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions